Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,405
Out of 5,241 analysts
135
Total ratings
53.7%
Success rate
31.86%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $22.75 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $73.18 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $630.30 | +34.86% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.96 | +818.37% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $0.4758 | +12,510.34% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $3.58 | +151.40% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $4.15 | +719.28% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $190.56 | +71.60% | 7 | Oct 15, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $434.31 | -35.30% | 5 | Jun 11, 2021 | |
| AKBA Akebia Therapeutics | Initiates: Overweight | $8 | $0.8951 | +793.75% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.89 | +5,085.19% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $330.75 | -10.81% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $130.50 | -34.10% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $39.43 | +21.73% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.35 | +589.66% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $27.73 | +159.65% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.15 | +334.78% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $95.60 | +4.60% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $237.98 | -15.54% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $70.28 | +20.94% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $15.55 | +105.79% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $16.64 | +1,204.09% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $59.77 | -19.69% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $14.54 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $294.30 | -47.67% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $49.81 | +132.88% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $6.81 | +1,456.53% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $11.94 | +134.51% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $193.73 | -57.67% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $566.80 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.82 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.75
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $73.18
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $630.30
Upside: +34.86%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.96
Upside: +818.37%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $0.4758
Upside: +12,510.34%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $3.58
Upside: +151.40%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $4.15
Upside: +719.28%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $190.56
Upside: +71.60%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $434.31
Upside: -35.30%
Akebia Therapeutics
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $0.8951
Upside: +793.75%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.89
Upside: +5,085.19%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $330.75
Upside: -10.81%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $130.50
Upside: -34.10%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $39.43
Upside: +21.73%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $4.35
Upside: +589.66%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $27.73
Upside: +159.65%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.15
Upside: +334.78%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $95.60
Upside: +4.60%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $237.98
Upside: -15.54%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $70.28
Upside: +20.94%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $15.55
Upside: +105.79%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $16.64
Upside: +1,204.09%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $59.77
Upside: -19.69%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $14.54
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $294.30
Upside: -47.67%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $49.81
Upside: +132.88%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $6.81
Upside: +1,456.53%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $11.94
Upside: +134.51%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $193.73
Upside: -57.67%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $566.80
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $2.82
Upside: -